Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2019-03-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
独立董事关于公司第七届董事会第十四次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters discussed at a specific board meeting, including related party transactions, profit distribution proposals, internal control self-evaluation, securities investment, remuneration, and appointment of auditors. It references compliance with company law, securities law, and stock exchange listing rules. The document is not a full annual report or audit report but rather an independent opinion on board meeting agenda items and related corporate governance matters. It is not a short announcement but a detailed opinion document. This fits best under Board/Management Information (MANG), as it relates to board meeting deliberations and independent directors' opinions on governance and management issues.
2019-03-25 Chinese
关于公司及子公司使用闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It details the board meeting approval, investment purpose, amount, types of products, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal announcement about a financing activity related to the company's capital management, specifically the use of idle funds for investment in financial products. It does not contain financial statements or quarterly/yearly results, nor is it a report or transcript. The document length is 4088 characters, which is relatively short and focused on a specific capital use decision. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-03-25 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2018 年年度报告全文" which translates to "2018 Annual Report Full Text" for Jinling Pharmaceutical Company Limited. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, business overview, risk factors, governance, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes comprehensive financial data, business analysis, and management commentary for the fiscal year 2018. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2018
2019-03-25 Chinese
关于公司董事长辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's chairman, including details about the resignation date, the impact on the board, and stock holdings of the resigning director. It does not contain financial data, audit information, or report content. It is clearly about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management change, not a report or announcement of a report publication.
2019-03-14 Chinese
关于控股子公司南京鼓楼医院集团宿迁市人民医院有限公司被确定为三级甲等综合医院的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Jinling Pharmaceutical Co., Ltd. regarding its controlling subsidiary, Suqian People's Hospital, being designated as a Grade III Class A comprehensive hospital by the Jiangsu Provincial Health Commission. The document states the official notification and the effective period of the hospital's new rating. It explicitly mentions that this designation has no significant short-term impact on the company's operating performance. The document is brief (539 characters) and does not contain any financial statements, detailed financial data, or management discussion. It is an official announcement about a regulatory or operational status update related to a subsidiary, not a financial report or detailed management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing about compliance or officer certification. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous official announcements that do not fit other categories.
2019-02-21 Chinese
关于南京新工医疗产业投资基金合伙企业（有限合伙）对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding an external investment by a related investment fund into a hospital entity. It details the investment amount, parties involved, business scope, risk factors, and measures to resolve potential conflicts of interest. The document is structured as a formal public announcement with no financial statements or detailed financial performance data. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The document length is about 3103 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on a capital investment transaction and related corporate governance measures, which aligns with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-02-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.